Related Experiment Videos
Rhythm control in atrial fibrillation: endpoints for device-based trials
1Cardiovascular Research Group, the University of Calgary, and Division of Cardiology, Calgary Health Region, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1 amgillis@ucalgary.ca
Heart Rhythm
|April 27, 2005
Summary
Newer pacemakers and implantable cardioverter defibrillators offer advanced atrial fibrillation (AF) detection. Device metrics can assess therapy effectiveness, but clinical outcomes must be linked to AF suppression.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Modern pacemakers and implantable cardioverter defibrillators (ICDs) possess advanced diagnostic capabilities.
- These devices can detect, store, and analyze atrial tachycardia and atrial fibrillation (AF) episodes, including frequency, duration, and onset timing.
Purpose of the Study:
- To explore the utility of device-based metrics as outcome measures for evaluating therapies aimed at preventing atrial fibrillation (AF).
- To discuss the advantages and limitations of various AF parameters obtainable from implantable devices.
Main Methods:
- Review of diagnostic features in contemporary pacemakers and ICDs.
- Analysis of potential outcome measures for AF prevention therapies, such as time to first recurrence, AF burden, and symptomatic episodes.
- Consideration of patient populations and specific hypotheses when selecting outcome measures.
Main Results:
- Implantable devices provide parameters like AF frequency, duration, burden, and recurrence intervals that can serve as outcome measures.
- Each parameter has unique advantages and limitations, influencing its suitability for specific research questions.
- Device-based metrics are appropriate for assessing pacing or pharmacologic therapies for AF prevention.
Conclusions:
- The choice of outcome measure should align with the specific characteristics and temporal patterns of AF being studied.
- Clinical studies require careful patient selection to target the appropriate arrhythmia substrate.
- Demonstrating a link between AF suppression and improved clinical outcomes (e.g., symptoms, quality of life, mortality) is crucial for validating device-based metrics.